Difference between revisions of "Vulvar cancer"
Jump to navigation
Jump to search
| Line 45: | Line 45: | ||
=Locally advanced or metastatic disease= | =Locally advanced or metastatic disease= | ||
| + | ''Due to its relative rarity, there are very few prospective trials in advanced and metastatic vulvar cancer. In clinical practice, many adopt regimens from the cervical cancer literature; see the [[Cervical_cancer|cervical cancer page]] for those regimens.'' | ||
| + | |||
==Paclitaxel monotherapy {{#subobject:635f43|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:635f43|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Revision as of 16:59, 26 November 2018
| Section editor | |
|---|---|
 |
Summer B. Dewdney, MD Chicago, IL |
2 regimens on this page
2 variants on this page
|
Guidelines
NCCN
Neoadjuvant therapy
Cisplatin & RT
| back to top |
RT: Radiation Therapy
Regimen
| Study | Evidence |
|---|---|
| Moore et al. 2011 | Phase II |
Chemoradiotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once per week
- Concurrent radiation therapy: 1.8 Gy x 32 fractions, for a dose of 57.6 Gy
One course
Subsequent treatment
- Surgical resection of residual disease (or biopsy to confirm CR)
References
- Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Mar;124(3):529-33. Epub 2011 Nov 9. link to original article contains protocol PubMed
Locally advanced or metastatic disease
Due to its relative rarity, there are very few prospective trials in advanced and metastatic vulvar cancer. In clinical practice, many adopt regimens from the cervical cancer literature; see the cervical cancer page for those regimens.
Paclitaxel monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Witteveen et al. 2009 | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycle for up to 10 cycles
References
- Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol. 2009 Sep;20(9):1511-6. Epub 2009 Jun 1. link to original article link to PMC article contains verified protocol PubMed